↓ Skip to main content

Dove Medical Press

Article Metrics

What’s in the pipeline? Drugs in development for autism spectrum disorder

Overview of attention for article published in Neuropsychiatric Disease and Treatment, February 2014
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • Good Attention Score compared to outputs of the same age (79th percentile)
  • High Attention Score compared to outputs of the same age and source (87th percentile)

Mentioned by

twitter
8 tweeters
googleplus
1 Google+ user

Citations

dimensions_citation
6 Dimensions

Readers on

mendeley
79 Mendeley
citeulike
1 CiteULike
Title
What’s in the pipeline? Drugs in development for autism spectrum disorder
Published in
Neuropsychiatric Disease and Treatment, February 2014
DOI 10.2147/ndt.s39516
Pubmed ID
Authors

Min Sung, Chee Hon Chin, Choon Guan Lim, Hwee Sen, Alvin Liew, Chau Sian Lim, Esperance Kashala, Shih Jen Weng

Abstract

Autism Spectrum Disorder (ASD) is a complex neurodevelopmental disorder with both core symptoms and associated symptoms (eg, irritability, aggression, and comorbidities) that affect both the individual and the family/systems around them. There have been recent advances in the understanding of the underlying pathophysiology of ASD pertaining to genetics, epigenetics, neurological, hormonal, and environmental factors that contribute to the difficulties found in individuals with ASD. With this improved understanding, there has been a shift in the application of psychopharmacology in ASD and its related disorders. A literature review was conducted to examine research published in the last 5 years between different classes of psychotropic medications and ASD. The broad scope of the existing literature for the use of conventional medications is summarized and novel medications are discussed.

Twitter Demographics

The data shown below were collected from the profiles of 8 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 79 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
France 1 1%
United States 1 1%
Unknown 77 97%

Demographic breakdown

Readers by professional status Count As %
Researcher 18 23%
Student > Ph. D. Student 14 18%
Student > Bachelor 12 15%
Student > Master 10 13%
Other 6 8%
Other 19 24%
Readers by discipline Count As %
Medicine and Dentistry 24 30%
Agricultural and Biological Sciences 19 24%
Psychology 14 18%
Unspecified 9 11%
Neuroscience 6 8%
Other 7 9%

Attention Score in Context

This research output has an Altmetric Attention Score of 6. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 10 March 2014.
All research outputs
#988,385
of 6,230,816 outputs
Outputs from Neuropsychiatric Disease and Treatment
#199
of 1,232 outputs
Outputs of similar age
#27,650
of 134,349 outputs
Outputs of similar age from Neuropsychiatric Disease and Treatment
#8
of 63 outputs
Altmetric has tracked 6,230,816 research outputs across all sources so far. Compared to these this one has done well and is in the 84th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,232 research outputs from this source. They receive a mean Attention Score of 4.7. This one has done well, scoring higher than 83% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 134,349 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 79% of its contemporaries.
We're also able to compare this research output to 63 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 87% of its contemporaries.